Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ABV-1701 (Vitargus) is an injectable, in-situ-forming hydrogel composed of oxidized hyaluronic acid (oxi-HA) and adipic acid dihydrazide (ADH). It is designed as a biodegradable vitreous substitute for use during vitrectomy surgery to treat retinal detachment and other conditions requiring ocular endotamponade. Unlike traditional gas or silicone oil tamponades, Vitargus forms a stable semisolid gel that adheres to the retina and maintains its position without requiring patients to remain face-down post-surgery. The hydrogel is fully biodegradable and does not require surgical removal. Early clinical studies indicate it improves patient comfort and visual acuity during recovery compared to current products[1][3][5][6][7][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ABV-1701.